Zoe Weaver Ohler

Zoe Weaver Ohler

Auto-generated profile, based on publicly available information

Zoe Weaver Ohler

Center for Advanced Preclinical Research, Center for Cancer Research, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
XXXiaoling Xu
Xiaoling Xu
Kay-Uwe WagnerKay-Uwe Wagner
Kay-Uwe Wagner
DLDenise Larson
Denise Larson
ZWZoë Weaver
Zoë Weaver
CLCuiling Li
Cuiling Li
CDChu-Xia Deng
Chu-Xia Deng

1 March 1999 in Molecular Cell
Verified
Journal Article
Closed access
XXXiaoling Xu
Xiaoling Xu
ZWZoë Weaver
Zoë Weaver
SLSteven P Linke
Steven P Linke
CLCuiling Li
Cuiling Li
JGJessica Gotay
Jessica Gotay
CDChu-Xia Deng
Chu-Xia Deng

1 December 2013 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
AWAnnette O. Walter
Annette O. Walter
RSRobert Tjin Tham Sjin
Robert Tjin Tham Sjin
HHHenry J. Haringsma
Henry J. Haringsma
KOKadoaki Ohashi
Kadoaki Ohashi
JSJing Sun
Jing Sun
AAAndrew Allen
Andrew Allen
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial–mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC. Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404–15. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317

17 December 1998 in Oncogene
Verified
Journal Article
Closed access
PDF file
SSShan-Xiang Shen
Shan-Xiang Shen
ZWZoë Weaver
Zoë Weaver
XXXiaoling Xu
Xiaoling Xu
CLCuiling Li
Cuiling Li
MWMichael Weinstein
Michael Weinstein
CDChu-Xia Deng
Chu-Xia Deng

1 March 2001 in Genes & Development
Verified
Journal Article
Open access
PDF file
DADuane M. Allen
Duane M. Allen
HPHenriette van Praag
Henriette van Praag
JRJasodhara Ray
Jasodhara Ray
ZWZoë Weaver
Zoë Weaver
CWChristopher J. Winrow
Christopher J. Winrow
CBCarrolee Barlow
Carrolee Barlow
Ataxia telangiectasia (A-T) is an autosomal recessive disease characterized by normal brain development followed by progressive neurodegeneration. The gene mutated in A-T (ATM) is a serine protein kinase implicated in cell cycle regulation and DNA repair. The role of ATM in the brain and the consequences of its loss on neuronal survival remain unclear. We studied the role of ATM in adult neural progenitor cells in vivo and in vitro to define the role of ATM in dividing and postmitotic neural cells from Atm-deficient (Atm−/−) mice in a physiologic context. We demonstrate that ATM is an abundant protein in dividing neural progenitor cells but is markedly down-regulated as cells differentiate. In the absence of ATM, neural progenitor cells of the dentate gyrus show abnormally high rates of proliferation and genomic instability.Atm−/− cells in vivo, and in cell culture, show a blunted response to environmental stimuli that promote neural progenitor cell proliferation, survival, and differentiation along a neuronal lineage. This study defines a role for ATM during the process of neurogenesis, demonstrates that ATM is required for normal cell fate determination and neuronal survival both in vitro and in vivo, and points to a mechanism for neuronal cell loss in progressive neurodegenerative diseases.

19 April 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
DLDelphine Lissa
Delphine Lissa
NTNobuyuki Takahashi
Nobuyuki Takahashi
PDParth Desai
Parth Desai
IMIrena Manukyan
Irena Manukyan
CSChristopher W. Schultz
Christopher W. Schultz
ATAnish Thomas
Anish Thomas
Molecular subtypes of small cell lung cancer (SCLC) defined by the expression of key transcription regulators have recently been proposed in cell lines and limited number of primary tumors. The clinical and biological implications of neuroendocrine (NE) subtypes in metastatic SCLC, and the extent to which they vary within and between patient tumors and in patient-derived models is not known. We integrate histology, transcriptome, exome, and treatment outcomes of SCLC from a range of metastatic sites, revealing complex intra- and intertumoral heterogeneity of NE differentiation. Transcriptomic analysis confirms previously described subtypes based on ASCL1, NEUROD1, POU2F3, YAP1, and ATOH1 expression, and reveal a clinical subtype with hybrid NE and non-NE phenotypes, marked by chemotherapy-resistance and exceedingly poor outcomes. NE tumors are more likely to have RB1, NOTCH, and chromatin modifier gene mutations, upregulation of DNA damage response genes, and are more likely to respond to replication stress targeted therapies. In contrast, patients preferentially benefited from immunotherapy if their tumors were non-NE. Transcriptional phenotypes strongly skew towards the NE state in patient-derived model systems, an observation that was confirmed in paired patient-matched tumors and xenografts. We provide a framework that unifies transcriptomic and genomic dimensions of metastatic SCLC. The marked differences in transcriptional diversity between patient tumors and model systems are likely to have implications in development of novel therapeutic agents.